The Mag-Bind® cfDNA Kit is designed for rapid and reliable isolation of circulating DNA from 500-4,000 µL plasma or serum samples. The Mag-Bind® cfDNA Kit can be processed manually or with automated platforms. The procedure eliminates the need for funnels and vacuum steps, providing hands-free operation in automated protocols.
The uniquely formulated binding buffer allows for large sample volumes to be processed in automated formats with 4 mL of serum and plasma being processed in 24-well plates. The magnetic response of the Mag-Bind® Particles CH allow for fast magnetization during steps requiring high volumes and the high binding capacity allows for reduced amounts of magnetic particles to be required, thus reducing the elution volume required. 4 mL serum or plasma can be eluted in 50 µL.
The system combines the reversible nucleic acid-binding properties of Mag-Bind® paramagnetic particles with a unique binding system that targets smaller DNA fragments (150-400 bp) and minimizes the binding of larger fragments, such as gDNA.
Read our app note on how to retrieve short fragments as short as 50 bp.
Strategies for retrieving cfDNA of short fragment lengths using Mag-Bind® cfDNA kit (M3298)
Electropherogram overlay of purified DNA from 4 mL serum. 4 mL of unspiked serum was purified using kits from Omega Bio-tek and Company Q following manufacturer’s recommended protocols. Purified DNA was analyzed on Agilent’s TapeStation® 2200.
Electropherogram overlay of purified DNA from 1 mL serum. 100 n of 200 bp sheared bacterial genomic DNA was spiked into 1 mL of serum and extracted using Omega Bio-tek’s Mag-Bind® cfDNA Kit and a comparable column-based kit from Company Q, following manufacturer’s recommended protocols. Purified DNA was analyzed on Agilent’s TapeStation® 2200. The Omega Bio-tek kit was able to capture the circulating, cell-free DNA with no genomic DNA contamination. In contrast, Company Q’s eluate contained high molecular weight fragments indicating the presence of genomic DNA in the circulating DNA isolation.